Orchestra BioMed Holdings, Inc. (OBIO)
Market: NASD |
Currency: USD
Address: 150 Union Square Drive
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Show more
📈 Orchestra BioMed Holdings, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$13.57
-
Upside/Downside from Analyst Target:
353.89%
-
Broker Call:
13
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Orchestra BioMed Holdings, Inc.
| Date | Reported EPS |
|---|
| 2025-05-12 | -0.49 |
| 2025-03-31 | -0.42 |
| 2024-11-12 | -0.41 |
| 2024-08-12 | -0.45 |
| 2024-08-11 | -0.45 |
| 2024-05-13 | -0.38 |
| 2024-05-12 | -0.38 |
| 2024-03-27 | -0.37 |
| 2024-03-26 | -0.37 |
| 2023-11-13 | -0.38 |
| 2023-11-12 | -0.38 |
| 2023-08-10 | -0.35 |
| 2023-08-09 | -0.35 |
| 2023-05-12 | -0.4 |
| 2023-05-11 | -0.4 |
| 2022-12-16 | - |
| 2022-12-15 | - |
📰 Related News & Research
No related articles found for "orchestra biomed".
